Rivastigmine for subcortical vascular dementia

References

• RománGC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med. Clin. N. Am. 86(3), 477–499 (2002).
   PubMed Web of Science ®Google Scholar
• RománGC. Vascular dementia: distinguishing characteristics, treatment, and prevention. J. Am. Geriatr. Soc. 51(Suppl. 5 Dementia), S296–S304 (2003).
   PubMed Web of Science ®Google Scholar
• RománGC. Stroke, cognitive decline and vascular dementia: the silent epidemic of the 21st century. Neuroepidemiology 22(3), 161–164 (2003).
   PubMed Web of Science ®Google Scholar
• RománGC, Royall DR. A diagnostic dilemma: is “Alzheimer's dementia” Alzheimer's disease, vascular dementia, or both? Lancet Neurol. 3(3), 141 (2004).
   PubMedGoogle Scholar
• ErkinjunttiT, Román G, Gauthier S, Feldman H, Rockwood K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 35(4), 1010–1017 (2004).
   PubMed Web of Science ®Google Scholar
• RománGC. Facts, myths, and controversies in vascular dementia. J. Neurol. Sci. 226(1–2), 49–52 (2004).
   PubMed Web of Science ®Google Scholar
• Iwasaki K, Kitamura Y, Ohgami Y, Mishima K, Fujiwara M. The disruption of spatial cognition and changes in brain amino acid, monoamine and acetylcholine in rats with transient cerebral ischemia. Brain Res. 709(2), 163–172 (1996).
   PubMed Web of Science ®Google Scholar
• Ni JW, Matsumoto K, Li HB, Murakami Y, Watanabe H. Neuronal damage and decrease of central acetylcholine level following permanent occlusion of bilateral common carotid arteries in rat. Brain Res. 673(2), 290–296 (1995).
   PubMed Web of Science ®Google Scholar
• YamamuroY, Iwano H, Sensui N, Hori K, Nomura M. Acetylcholine in the hippocampus during the discrimination learning performance in a rat model of chronic cerebral ischaemia. Neuroreport 7(11), 1837–1840 (1996).
   PubMed Web of Science ®Google Scholar
• TogashiH, Matsumoto M, Yoshioka M, Hirokami M, Minami M, Saito H. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci. Lett. 166(1), 117–120 (1994).
   PubMed Web of Science ®Google Scholar
• TogashiH, Kimura S, Matsumoto M, Yoshioka M, Minami M, Saito H. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke 27(3), 520–525 (1996).
   PubMed Web of Science ®Google Scholar
• TohgiH, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J. Neural. Transm. 103(10), 1211–1220 (1996).
   PubMed Web of Science ®Google Scholar
• GottfriesCG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia 5(3–4), 163–167 (1994).
   PubMedGoogle Scholar
• WallinA, Gottfries CG. Biochemical substrates in normal aging and Alzheimer's disease. Pharmacopsychiatry 23(Suppl. 2), 37–43 (1990).
   PubMed Web of Science ®Google Scholar
• WallinA, Sjögren M, Blennow K, Davidsson P. Decreased cerebrospinal fluid acetylcholinesterase activity in patients with subcortical vascular dementia. J. Neurol. Sci. 226(1–2), 105 (2004).
   PubMedGoogle Scholar
• Selden NR, Gitelman DR, Salamon-Murayama N, Parrish TB, Mesulam MM. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 121(Pt 12), 2249–2257 (1998).
   PubMed Web of Science ®Google Scholar
• Swartz RH, Black SE. How common is vascular compromise of cholinergic white matter pathways in a memory clinic sample? J. Neurol. Sci. 281, 203–204 (2002).
   Google Scholar
• Swartz RH, Sahlas DJ, Black SE. Strategic involvement of cholinergic pathways and executive dysfunction: does location of white matter signal hyperintensities matter? J. Stroke Cerebrovasc. Dis. 12, 29–36 (2003).
   PubMedGoogle Scholar
• MesulamM, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology 60(7), 1183–1185 (2003).
   PubMed Web of Science ®Google Scholar
• Sato A, Sato Y, Uchida S. Activation of the intracerebral cholinergic nerve fibers originating in the basal forebrain increases regional cerebral blood flow in the rat's cortex and hippocampus. Neurosci. Lett. 361, 90–93 (2004).
   PubMed Web of Science ®Google Scholar
• Hamel E. Cholinergic modulation of the cortical microvascular bed. Prog. Brain Res. 145, 171–178 (2004).
   PubMed Web of Science ®Google Scholar
• Sato A, Sato Y, Uchida S. Regulation of regional cerebral blood flow by cholinergic fibers originating in the basal forebrain. Int. J. Dev. Neurosci. 19, 327–237 (2001).
   PubMed Web of Science ®Google Scholar
• BiesoldD, Inanami O, Sato A, Sato Y. Stimulation of the nucleus basalis of Meynert increases cerebral cortical blood flow in rats. Neurosci. Lett. 98, 39–44 (1989).
   PubMed Web of Science ®Google Scholar
• CauliB, Tong XK, Rancillac A et al. Cortical GABA interneurons in neurovascular coupling: relays for subcortical vasoactive pathways. J. Neurosci. 24, 8940–8949 (2004).
   Google Scholar
• Lacombe P, Sercombe R, Vaucher E, Seylaz J. Reduced cortical vasodilatory response to stimulation of the nucleus basalis of Meynert in the aged rat and evidence for a control of the cerebral circulation. Ann. NY Acad. Sci. 826, 410–415 (1997)
   PubMedGoogle Scholar
• Uchida S, Suzuki A, Kagitani F, Hotta H. Effects of age on cholinergic vasodilation of cortical cerebral blood vessels in rats. Neurosci. Lett. 294, 109–112 (2000).
   PubMed Web of Science ®Google Scholar
• CeravoloR, Volterrani D, Tognoni G et al. Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. Clin. Neuropharmacol. 27, 166–170 (2004).
   PubMed Web of Science ®Google Scholar
• LojkowskaW, Ryglewicz D, Jedrzejczak T et al. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J. Neurol. Sci. 216, 119–126 (2003).
   PubMed Web of Science ®Google Scholar
• Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am. J. Geriatr. Psychiatry 11(2), 131–145 (2003).
   PubMed Web of Science ®Google Scholar
• Desai A, Grossberg G. Review of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders. Expert. Opin. Pharmacother. 2(4), 653–666 (2001).
   PubMedGoogle Scholar
• FarlowMR. Update on rivastigmine. Neurologist 9(5), 230–234 (2003).
   PubMed Web of Science ®Google Scholar
• O’Brien KK, Saxby BK, Ballard CG et al. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 13, 231–239 (2003).
   PubMedGoogle Scholar
• EmreM, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351(24), 2509–2518 (2004).
   PubMed Web of Science ®Google Scholar
• Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 21(7), 453–478 (2004).
   PubMed Web of Science ®Google Scholar
• PolinskyRJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin. Ther. 20(4), 634–647 (1998).
   PubMed Web of Science ®Google Scholar
• Kennedy JS, Polinsky RJ, Johnson B et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J. Clin. Psychopharmacol. 19(6), 513–521 (1999).
   PubMed Web of Science ®Google Scholar
• Darreh-ShoriT, Almkvist O, Guan ZZ et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 59(4), 563–572 (2002).
   PubMed Web of Science ®Google Scholar
• Darreh-ShoriT, Hellstrom-Lindahl E, Flores-Flores C, Guan ZZ, Soreq H, Nordberg A. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J. Neurochem. 88(5), 1102–1113 (2004).
   PubMed Web of Science ®Google Scholar
• AlmkvistO, Darreh-Shori T, Stefanova E, Spiegel R, Nordberg A. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. Eur. J. Neurol. 11(4), 253–261 (2004).
   PubMed Web of Science ®Google Scholar
• RacchiM, Mazzucchelli M, Porrello E, Lanni C, Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol. Res. 50(4), 441–451 (2004).
   PubMed Web of Science ®Google Scholar
• FinkelSI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin. Ther. 26(7), 980–990 (2004).
   PubMed Web of Science ®Google Scholar
• Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst. Rev. (3), CD003672 (2003).
   PubMedGoogle Scholar
• MorettiR, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in vascular dementia. Expert Opin. Pharmacother. 5(6), 1399–1410 (2004).
   PubMed Web of Science ®Google Scholar
• RománGC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol. 1(7), 426–436 (2002).
   PubMed Web of Science ®Google Scholar
• RománGC, Royall DR. Executive control function: a rational basis for the diagnosis of vascular dementia. Alzheimer Dis. Assoc. Disord. 13(Suppl. 3), S69–S80 (1999).
   PubMedGoogle Scholar
• RománGC, Sachdev P, Royall DR et al. Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J. Neurol. Sci. 226(1–2), 81–87 (2004).
   PubMed Web of Science ®Google Scholar
• MorettiR, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur. J. Neurol. 8(4), 361–362 (2001).
   PubMed Web of Science ®Google Scholar
• MorettiR, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J. Neurol. Sci. 203, 141–146 (2002).
   PubMed Web of Science ®Google Scholar
• Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur. J. Neurol. 7(2), 159–169 (2000).
   PubMed Web of Science ®Google Scholar
• ErkinjunttiT, Skoog I, Lane R, Andrews C. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. Int. J. Clin. Practice 56(10), 791–796 (2002).
   PubMed Web of Science ®Google Scholar
• ErkinjunttiT, Skoog I, Lane R, Andrews C. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. Int. J. Clin. Practice 57(9), 756–760 (2003).
   PubMed Web of Science ®Google Scholar